I. COMMENCED TRADING IN AUGUST

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units (M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%


INITIAL OFFERINGS

Osiris
Therapeutics
Inc.
(OSIR)1

5/12/06

8/4/06

3.5S

$11

27.14

Jefferies and Co., Lazard Capital Markets, Leerink Swann & Co.

$38.5

$298.5

OVERALLOTMENT OPTIONS

Replidyne Inc.
(RDYN)2

4/6/06

8/2/06

0.5S

$10

26.93

Merrill Lynch & Co.,Morgan Stanley & Co. (co-lead) Cowen & Co., Pacific Growth Equities

$5

$269.3

Total: $43.5M

Number of IPOs in August: 1

Average value of August IPOs: $38.5M

Number of IPOs in 2006: 19

Total raised in IPOs in 2006: $867.98M

Average value of IPOs in 2006: $45.68M

FOLLOW-ON OFFERINGS

Company
(Symbol)#

Date
Filed

Date
Comm.

Shares/
Units
(M)

Price

Shares
Out
(M)@

Lead, Other
Underwriters

Gross
(M)

Post-
Offering
Market
Cap (M)%


CV
Therapeutics
Inc.
(CVTX)3

4/18/06

8/16/06

10.35S

$9.50

56.66

Lehman Brothers, Merrill Lynch (co-lead)

$98.33

$538.3

Total: $98.33

Number of follow-on offerings in August: 1

Average value of August follow-ons: $98.33

Number of follow-on offerings in 2006: 26

Total raised in follow-ons in 2006: $2,416.73M

Average value of follow-ons in 2006: $92.95M


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ This column reflects the shares outstanding following the offering, when disclosed.

% Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

1. Osiris raised $38.5M in an IPO. Underwriters have an option to purchase up to 525,000 additional shares to cover overallotments.

2. Underwriters of Replidyne's IPO that priced in June exercised their option to purchase about 500,000 additional shares. The IPO totaled about 5M shares and $50M in gross proceeds.

3. CV Therapeutics raised about $98.33M in a follow-on offering. Totals include the underwriters' purchase of 1.35M shares per their overallotment option.

II. FILED AND PENDING

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed

Shares/
Units
(M)

Price
Range

Shares
Out
(M)
@

Lead, Other
Underwriters

Value
(M)


INITIAL OFFERINGS

Achillion
Pharmaceuticals
Inc.
(ACHN)1

4/3/06

N/A

N/A

N/A

Cowen & Co., CIBC World Markets (co-lead), JMP Securities

$75

ActivBiotics
Inc.
(ACTV)2

8/14/06

N/A

N/A

N/A

HSBC Securities, Needham & Co., BMO Capital Markets, Susquehanna Financial

$46

Affymax Inc.
(AFFY)3

7/28/06

N/A

N/A

N/A

Morgan Stanley & Co., Cowen and Co. (co-lead), Thomas Weisel Partners (co-lead), RBC Capital Markets

$115

BioVex
Group Inc.
(BVEX)4

6/20/06

N/A

N/A

N/A

Janney Montgomery Scott, Stifel Nicolaus

$45

Cadence
Pharmaceuticals
Inc.
(CADX)5

7/17/06

N/A

N/A

N/A

Merrill Lynch & Co., Deutsche Bank Securities (co-lead), Pacific Growth Equities, JMP Securities

$86.25

Catalyst
Pharmaceutical
Partners Inc.
(CPRX)6

7/25/06

N/A

N/A

N/A

First Albany Capital, Stifel Nicolaus (co-lead)

$40.25

Emergent
BioSolutions
Inc.
(EBSI)7

8/15/06

N/A

N/A

N/A

JP Morgan Securities, Cowen and Co. (co-lead), HSBC Securities

$86.25

ImaRx
Therapeutics
Inc.
(IMRX)8

5/19/06

N/A

N/A

N/A

CIBC World Markets, Jefferies & Co., First Albany Capital

$75

Light Sciences
Oncology Inc.
(LSON)9

4/21/06

N/A

N/A

N/A

Cowen & Co., Wachovia Securities (co-lead), Jefferies & Co., Thomas Weisel Partners

$86.25

Metabolix
Inc.
(MBLX)10

7/14/06

N/A

N/A

N/A

Piper Jaffray & Co., Jefferies & Co., Thomas Weisel Partners, Ardour Capital Investments

$86.25

Molecular
Insight
Pharmaceuticals
Inc.
(MIPI)11

11/8/05

N/A

N/A

N/A

Piper Jaffray & Co., Cowen & Co. (co-lead), Oppenheimer & Co., Roth Capital Partners

$57.5

Perlegen
Sciences Inc.
(PERL)12

4/10/06

N/A

N/A

N/A

Lehman Brothers, Deutsche Bank Securities (co-lead), Piper Jaffray & Co., Allen & Co.

$115

Pharmasset
Inc.
(VRUS)13

5/9/06

N/A

N/A

N/A

Banc of America Securities, UBS Investment Bank (co-lead), JMP Securities

$75

PTC
Therapeutics
Inc.
(PTCT)14

3/31/06

N/A

N/A

N/A

Morgan Stanley & Co., JP Morgan Securities (co-lead), Pacific Growth Equities

$86.25

Sucampo
Pharmaceuticals
Inc.
(SCMP)15

6/19/06

N/A

N/A

N/A

Banc of America Securities, Deutsche Bank Securities (co-lead), Leerink Swann & Co.

$86.25

Trubion
Pharmaceuticals
Inc.
(TRBN)16

6/2/06

N/A

N/A

N/A

Morgan Stanley & Co., Banc of America Securities (co-lead), Pacific Growth Equities, Lazard Capital Market

$86.25

FOLLOW-ON OFFERINGS

Viragen Inc.
(AMEX:VRA)17

7/31/06

77S and 77W

$0.279

N/A

Dawson James Securities

$21.5

WITHDRAWN AND POSTPONED

Company
(Symbol/
Proposed
Symbol)#*

Date
Filed/
Date
Pulled

Shares/ Units
(M)

Price Range

Shares Out (M)@

Lead, Other Underwriters

Value
(M)


Amicus
Therapeutics
Inc.
(AMTX)18

5/17/06/
8/2/06

N/A

N/A

N/A

Morgan Stanley & Co., Goldman, Sachs & Co. (co-lead), Pacific Growth Equities

$86.25


Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing.
* Stock symbols for companies seeking to complete IPOs are proposed.
AMEX = American Stock Exchange.
@ This column reflects the shares outstanding following the offering, when disclosed.
N/A = Not available, applicable or reported.
1. Achillion filed to raise up to $75M in an IPO.
2. ActivBiotics filed to raise up to $46M in an IPO.
3. Affymax filed to raise up to $115M in an IPO.
4. BioVex filed to raise up to $45M in an IPO.
5. Cadence filed to raise up to $86.25M in an IPO.
6. Catalyst filed to raise up to $40.25M in an IPO.
7. Emergent filed to raise up to $86.25M in an IPO.
8. ImaRx filed to raise up to $75M in an IPO.
9. Light Sciences Oncology filed to raise up to $86.25M in an IPO.
10. Metabolix filed to raise up to $86.25M in an IPO.
11. Molecular Insight filed to raise up to $57.5M in an IPO.
12. Perlegen filed to raise up to $115M in an IPO.
13. Pharmasset filed to raise up to $75M in an IPO.
14. PTC Therapeutics filed to raise up to $86.25M in an IPO.
15. Sucampo filed to raise up to $86.25M in an IPO.
16. Trubion filed to raise up to $86.25M in an IPO.
17. Viragen filed to raise up to $21.5M in a follow-on offering of stock and warrants.
18. Amicus cited market conditions in withdrawing its proposed IPO.